Mechanistically, iberverin treatment downregulates the SLC7A11 mRNA level and promotes GPX4 ubiquitin—proteasome degradation, resulting in the downregulation of the ferroptosis defense proteins GPX4 and SLC7A11, eventually leading to excessive lipid peroxidation and ferroptosis in HCC cells (Figure 6). This evidence concerns the gene GPX4 and hepatocellular carcinoma.